(603669)"Lionco Pharmaceutical Group Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 603669 · · 13 pages · Chinese
Lionco Pharmaceutical Group Co., Ltd. on 6ix
Earlier from Lionco Pharmaceutical
- (603669)"Lionco Pharmaceutical Group Co., Ltd."Announcement on Conversion Results of Convertible Bonds and Share Changes
- Announcement on Obtaining Drug Registration Certificate for Isavuconazonium Sulfate for Injection by Wholly-owned Subsidiary
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
- Announcement on Resolutions of the 12th Meeting of the 5th Board of Directors
- Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026
Later from Lionco Pharmaceutical
- (603669)"Lionco Pharmaceutical Group Co., Ltd."First Indicative Announcement on Redemption at Maturity and Delisting of "Lionco Convertible Bonds"
- (603669)"Lionco Pharmaceutical Group Co., Ltd."Second Indicative Announcement on Redemption at Maturity and Delisting of "Lionco Convertible Bonds"
- (603669)"Lionco Pharmaceutical Group Co., Ltd."Third Indicative Announcement on Redemption at Maturity and Delisting of "Lionco Convertible Bonds"
Follow Lionco Pharmaceutical into a list and get an email when it puts out news.
Follow Lionco Pharmaceutical